Agenus (AGEN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Moomoo News12:31 ET · Ratings
Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump
MT NewswiresNov 27 10:12 ET
Express News | Agenus Inc - Plan Includes 60% Reduction in Annual External Expenditures
ReutersNov 27 08:15 ET
Express News | Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
ReutersNov 27 08:15 ET
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
TipRanksNov 25 01:10 ET · Ratings
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
Moomoo NewsNov 19 03:36 ET · Ratings

Comments

Jaguar8

Yesterday 21:15

NEWS

$Agenus (AGEN.US)$
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...

Martin J

Nov 22 10:50

🚀🚀🚀

Share Your Profit/Loss

6

2

Jaguar8

Nov 7 09:02

NEWS

$Agenus (AGEN.US)$
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...

1

Jaguar8

Sep 13 10:46

NEWS

$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...

Trytosaveabit

Sep 9 14:14

Hehehe! They going to fudge the results at today’s conference?

$Agenus (AGEN.US)$ Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...

4

AGEN Agenus

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target